Mesoblast (NASDAQ: MESO) draws US$50M, refinances high-cost debt
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Mesoblast Limited has drawn down US$50 million from a five-year, non-dilutive credit facility provided by existing shareholder and director Dr. Gregory George. Together with US$122 million of cash as of March 30, 2026, this strengthens funding for commercial operations and its growth pipeline.
The new facility carries a fixed interest rate of 8.00% per annum with a five-year interest-only period and can be repaid at any time without prepayment or exit fees. It is secured solely by the Temcell royalty, leaving Mesoblast’s other material assets and intellectual property unencumbered.
Positive
- US$50 million five-year facility at 8% provides non-dilutive funding and is described as replacing higher-cost, short-term NovaQuest debt, which can strengthen liquidity and reduce interest burden.
- Security limited to Temcell royalty leaves other material assets and intellectual property unencumbered, preserving flexibility for future strategic partnerships and licensing transactions.
Negative
- None.
Insights
Mesoblast refinances into cheaper, longer-term debt while preserving key assets.
Mesoblast has accessed a US$50 million, five-year facility at a fixed 8.00% interest rate from an existing shareholder-director. Management indicates that this will retire higher-cost NovaQuest debt and remove short-term obligations, simplifying the liability profile.
The facility is interest-only for five years, secured solely by the Temcell royalty, and has no prepayment or exit fees. This combination supports liquidity and balance sheet flexibility while avoiding equity dilution. Actual benefit will depend on execution of commercial plans funded by this capital.
Because the facility does not encumber other material assets or intellectual property, Mesoblast states it remains free to enter strategic partnerships and licensing deals. Future disclosures on debt retirement progress and revenue streams linked to the Temcell royalty will be important to understand long-term coverage of this obligation.
Key Figures
New facility size: US$50 million
Interest rate: 8.00% per annum
Cash balance: US$122 million
+3 more
6 metrics
New facility size
US$50 million
Five-year non-dilutive credit facility from shareholder/director
Interest rate
8.00% per annum
Fixed rate on new five-year facility
Cash balance
US$122 million
Cash at March 30, 2026
Facility term
Five years
Interest-only period from initial draw
Patent portfolio size
Over 1,000 patents or applications
Global IP covering compositions, manufacturing and indications
IP protection horizon
Through at least 2044
Commercial protection in major markets
Key Terms
non-dilutive facility, Temcell royalty, mesenchymal stromal cell, steroid-refractory acute graft versus host disease, +1 more
5 terms
non-dilutive facility financial
"MESOBLAST DRAWS US$50 MILLION FROM FIVE-YEAR NON-DILUTIVE FACILITY"
Temcell royalty financial
"will be secured solely with the Temcell1 royalty."
mesenchymal stromal cell medical
"first FDA-approved mesenchymal stromal cell (MSC) therapy."
Mesenchymal stromal cells are a type of adult cell found in bone marrow, fat and other tissues that can act like a repair crew, supporting tissue healing, reducing inflammation and helping other cells grow. Investors care because these cells are the basis for many experimental therapies and diagnostics; clinical success, manufacturing scale-up, safety and regulatory approval determine commercial potential and can strongly affect a company’s valuation.
steroid-refractory acute graft versus host disease medical
"for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD)"
An aggressive complication after an allogeneic stem cell or bone marrow transplant where donor immune cells attack the patient’s organs and tissues, and that does not improve after standard high‑dose steroid treatment. Investors should care because it signals a high unmet medical need, often requires additional therapies, longer hospital stays and complex clinical trials, and therefore drives demand, pricing and regulatory attention for new treatments.
forward-looking statements regulatory
"This press release includes forward-looking statements that relate to future events"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the month of June 2026
Commission File Number 001-37626
Mesoblast Limited
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
Australia
(Jurisdiction of incorporation or organization)
(Jurisdiction of incorporation or organization)
Silviu Itescu
Chief Executive Officer and Executive Director
Level 38
55 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☑ Form 40-F ☐
INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K
On June 25, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.
Mesoblast Limited | ||||||||||||||
| /s/ Paul Hughes | ||||||||||||||
| Paul Hughes | ||||||||||||||
| Company Secretary | ||||||||||||||
Dated: June 25, 2026
INDEX TO EXHIBITS
| Item | ||||||||
99.1 | Press release of Mesoblast Ltd, dated June 25, 2026. | |||||||
MESOBLAST DRAWS US$50 MILLION FROM FIVE-YEAR NON-DILUTIVE FACILITY Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline New York, USA: June 24 and Melbourne, Australia: June 25, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it drew down US$50 million from its five-year facility provided by existing Mesoblast shareholder and director Dr. Gregory George. Mesoblast had US$122 million cash at March 30, 2026. In aggregate Mesoblast is well funded to invest in its commercial operations and growth pipeline, and opitimize its capital structure by retiring the higher cost NovaQuest Capital Management LLC debt facility eliminating the short-term debt obligations. The credit-line has a fixed interest rate of 8.00% per annum, a substantial reduction from prior facilities, with a five-year interest only period (from initial draw), and will be secured solely with the Temcell1 royalty. The facility can be repaid at any time without incurring early prepayment or make-whole fees, does not include exit fees. Mesoblast Chief Executive Silviu Itescu said, “Mesoblast’s balance sheet is strengthened by a favorable long-term facility with elimination of short-term high-cost debt. The facility does not encumber any of our material assets or intellectual property, enabling unrestricted entry into strategic partnerships or licensing transactions.” About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Exhibit 99.1
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes 1. TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact: Corporate Communications / Investors Paul Hughes T: +61 3 9639 6036 Media – Global Media – Australia Rubenstein BlueDot Media Caroline Nelson Steve Dabkowski T: +1 703 489 3037 T: +61 419 880 486 E: cnelson@rubenstein.com E: steve@bluedot.net.au
FAQ
What financing did Mesoblast (MESO) announce in the June 2026 6-K?
Mesoblast disclosed drawing US$50 million from a five-year, non-dilutive credit facility provided by existing shareholder and director Dr. Gregory George. The company plans to use this alongside existing cash to support commercial operations, its growth pipeline and optimize its capital structure.
What are the key terms of Mesoblast’s new US$50 million facility?
The facility bears a fixed 8.00% annual interest rate with a five-year interest-only period from initial draw. It can be repaid at any time without early prepayment, make-whole, or exit fees, giving Mesoblast flexibility in managing its debt profile over the term.
How does the new facility affect Mesoblast (MESO) debt and capital structure?
Mesoblast states the facility will help retire its higher-cost NovaQuest Capital Management debt and eliminate related short-term obligations. This is intended to optimize the capital structure by extending maturities, lowering borrowing costs, and providing non-dilutive funding for commercial and pipeline investments.
What collateral secures Mesoblast’s new US$50 million credit line?
The facility is secured solely by the Temcell royalty. Mesoblast emphasizes that none of its other material assets or intellectual property are encumbered, which it believes preserves flexibility to enter strategic partnerships or licensing deals involving its broader cell therapy portfolio.
How much cash did Mesoblast report having before this new drawdown?
Mesoblast reported US$122 million in cash as of March 30, 2026. Together with the new US$50 million facility, the company states it is well funded to invest in commercial operations, advance its product pipeline, and continue optimizing its capital structure.
What products and indications is Mesoblast (MESO) currently focused on?
Mesoblast highlights Ryoncil, an FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease. It is also developing remestemcel-L and rexlemestrocel-L candidates for additional inflammatory diseases, heart failure and chronic low back pain, supported by a broad global intellectual property portfolio.